For the identification of severe MASH (NAS ≥ 5), another study found that the addition of PNPLA3 GG trait to a model including age, sex, BMI, T2DM and ALT, augmented the AUC from 0.75 to 0.77, while for the prediction of advanced fibrosis (F3–F4), adding PNPLA3 GG trait to the baseline model yielded to AUC 0.78 [56]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.